This article is more than 5 years old. Information may no longer be current.

Cerapedics receives CE mark and TGA listing for new bone graft

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cerapedics recently announced it has received CE mark in Europe and Therapeutic Goods Administration listing in Australia for its new i-FACTOR Flex FR biologic bone graft.

The new biologic bone graft features the company’s proprietary synthetic small peptide (P-15) bone graft technology with the addition of purified silk fibers, according to a company press release.

The i-FACTOR Flex FR is based on original P-15 technology developed by Cerapedics to support bone growth through cell attachment and osteoblast differentiation. The new product includes silk from bombyx mori moth larva that is purified to remove the protein sericin, which results in biocompatible fibroin fibers that enhance cohesion and mechanical properties, according to the release.

More than 60 procedures have been successfully completed thus far using i-FACTOR Flex FR biologic bone graft, primarily in spinal fusion applications. The company introduced the product in a limited market release in order to obtain feedback from surgeons, according to the release.

Reference: www.cerapedics.com.